Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants

NCT02308540 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT02308540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02308540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants
Lead sponsor
PATH
Phase
Phase 1/2
Overall status
Completed
Start date
January 12, 2015
Completion date
November 3, 2016
Enrollment
346 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease